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Is inhaled heparin a viable therapeutic option in inhalation injury? 
Abstract
Inhalation injury is a major cause of morbidity and mortality in patients with burns. Presence of airways injury adds to the need 
of fluid supplementation, increases risk of pulmonary complications. Due to many mechanisms involved in pathophysiology the 
treatment is complex. Among them the formation of fibrin casts inside airways constitutes a prominent element. The material re-
siding in tracheobronchial tree causes ventilation-perfusion mismatch, complicates mechanical ventilation, provides a medium for 
bacterial growth. Many studies of animal models and single centre human studies investigated inhaled anticoagulation regimens 
employing heparin in management of inhalation injury. Simultaneously safety, especially in connection with possible bleeding risk, 
was the subject of research. The results suggest positive impact on treatment results, with low risk of side effects. This paper 
revise the available clinical data on inhaled heparin use in patients with burns.
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Introduction
Inhalation injury is an independent risk fac-
tor contributing to high mortality in patients with 
burns [1–3]. A  risk of airways injury increases 
with total body surface affected by the burn. 
According to the data from the United States, 
a burn of 20% of total body surface area corre-
sponds to a 2.2% chance of inhalation injury. On 
the other hand, when 80−99% of body surface is 
affected, the airways are also damaged in 14% of 
patients [4]. Nonetheless, a clinically significant 
inhalation injury can be present despite a lack of 
cutaneous burns [5]. Acute lung injury in adult, 
hospitalised patients with burns is estimated at 
3−30% of all cases. Differences are caused by 
lack of generally accepted diagnostic criteria for 
such an injury [6–9]. In comparison with paedi-
atric population, the occurrence of acute lung in-
jury is estimated at 3−15% [10, 11]. Furthermore, 
if a  subgroup with the most severe injury, in 
which burn severity resulted in patients death, 
the percentage of individuals with inhalation 
injury reaches 50% [7]. Available Polish data on 
inhalation injury in burns patients is of poor 
quality. Similarly to global data, Polish data are 
almost exclusively based on a   single centre 
experience. Analysis of hospital admissions to 
regional burn centre during a  two-year period 
showed that isolated airways injury was present 
only among 0.5% of patients. Hospitalisations 
of subjects with burn of unspecified body region 
(which can include inhalation injury) account-
ed for 50.6% of the analysed admissions [12]. 
Available data on paediatric population does not 
report cases of inhalation injury [13].
Pathophysiology
Despite constant progress in the field of 
burns pathophysiology, many issues are still 
unresolved, therefore, treatment is mainly based 
on symptomatic therapy [14]. A few mechanisms 
are responsible for damage to the respiratory tract 
and lung tissue (called inhalation injury or smoke 
inhalation injury) caused by inhalation of various 
irritants. Thermal injury, excluding damage cau-
sed by steam, is limited to the upper airways. De-
eper structures, like the tracheobronchial tree, are 
damaged by chemical irritants with hydrophobic 
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properties and particulate matter [15]. Chemical 
irritation of the airways’ mucosa stimulates nerve 
fibres present in the airways and causes produc-
tion of various proinflammatory cytokines [16, 
17]. It results in a considerable increase of blood 
flow and capillary permeability to proteins in the 
pulmonary vascular bed [18]. Simultaneously, 
reaction to released chemoattractants causes ac-
cumulation of immunocompetent cells, mainly 
neutrophils, in the respiratory system. Thermal 
and chemical injury damages epithelial lining of 
the respiratory tract mucosa, which sheds into 
the airways’ lumen [19]. All the aforementioned 
mechanisms add to accumulation of material 
in the alveoli and bronchial tree. The material 
consists of mucus, inflammatory cells, exfoliated 
epithelial cells and fibrin. On the other side, 
vascular changes contribute to the congestion of 
surrounding tissues. [20, 21]. Finally, the affect-
ed airways became partially or fully obstructed, 
which in succession causes collapse of associated 
alveoli. At the same time fibrinogen present in 
the exudate transforms into fibrin. Over time the 
initially liquid material inside the airways forms 
casts which are hard to mobilise and evacuate 
[22]. Furthermore, the presence of fibrin disrupts 
the function of surfactant changing the surface 
tension. It adds to the atelectasis caused by lack 
of airways patency preventing effective alveolar 
ventilation. Simultaneously, in open parts of the 
lung, local areas of compensatory emphysema 
develop. Increasing ventilation-perfusion mis-
match results in acute respiratory insufficiency. 
In cases when mechanical ventilation becomes 
necessary, it may be needed to use higher 
inspiratory pressures, which subsequently, may 
cause pressure injury (barotrauma) [22, 23]. In 
the first 24−48 hours after inhalation injury, it 
presents itself as obstructive ventilatory defect, 
as a manifestation of airways occlusion by secre-
tions. Therefore, therapy at this stage consists of 
airways toilet through techniques which include 
airway suction and therapeutic bronchoscopy. 
Simultaneously, intravenous fluid regulation 
allows control over the local oedema in the air-
ways. However, it is worth noting that inhalation 
injury in burn patients is connected with higher 
need for intravenous infusion in comparison 
to patients without airways damage [24, 25]. 
A   reduction in airways clearance caused by 
mucosa damage and t h e  presence of fibrin 
promotes bacterial growth in the residual secre-
tions. It increases the risk of secondary bacterial 
pneumonia, which usually develops between 3–6 
day after inhalation injury. Pathogens causing this 
inflammation commonly arise from patients’ own 
bacterial flora, present during hospital admission 
[26]. Consequently, at this
 point infection control 
becomes the main concern in management. It 
is especially important given the 25% mortality 
of pneumonia in this group of patients [26, 27]. 
Animal models
The aforementioned mechanisms justify 
the use of inhalation anticoagulants to limit 
formation and facilitate the evacuation of fibrin 
casts causing airways obstruction. Among anti-
coagulants inhaled,
 
heparin is often used to this 
end. It is based on results of many studies on 
animal models. It has been proved that hepa-
rin used alone or in combination with other 
anticoagulants has a  positive impact on the 
ventilation-perfusion mismatch, alveolar-arterial 
gradient, post-burn elevation of pulmonary blood 
flow, mean airway pressure [28–31]. Nonetheless, 
some of the previously
 mentioned influences 
were proven only for heparin used in connection 
with other medication [28, 29].
Clinical trials
Systematic search of literature allows to find 
7 retrospective clinical trials pertaining therapy 
of inhalation injury in humans using nebulised 
heparin in combination with N-acetylcysteine. 
The addition of this mucolytic is motivated 
by impairment of airway clearance during 
inhalation injury and antioxidant properties of 
N-acetylcysteine. Six trials investigated potential 
benefits of inhaled anticoagulation in patients 
with inhalation injury, the seventh was concerned 
with safety of nebulised heparin. The oldest ret-
rospective study by Desai et al. was performed 
on a  group of paediatric patients. Therapeutic 
protocol used 5000 I.U. of heparin and 3 millil-
itres of 20% solution of N-acetylceysteine. Both 
medications were administered by nebulisation 
every 4 hours. Therapy was continued for 7 days. 
Significant reduction in mortality was noted for 
the treatment group [32]. A study by Holt from 
2008 used similar treatment protocol, but also 
included salbutamol. The results stand in op-
position to the outcomes obtained by Desai. 
Initial analysis covering both paediatric and 
adult group failed to prove significant differences 
between treatment and control groups. Further 
analysis of 25 paediatric patients also failed to 
demonstrate statistically significant differences. 
It is worth noting that the use of inhaled antico-
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Table 1. Studies concerning use of inhaled heparin in patients with inhalation injury
Study Number of 
patients
Inhalation treatment protocol Results
Desai 1998 90 5000 I.U. heparin + 3 ml 20% N-acetylcysteine every 4 h for 
7 days
Lower mortality, less cases of reintubation 
and atelectasis
Holt 2008 150 5000 I.U. heparin + 3 ml 20% N-acetylcysteine every 4 h for 
7 days + salbutamol 2,5 mg (at physicians discrecy)
No significant differences between groups
Rivero 2007 16 10000 I.U. heparin + 3 ml 20% N-acetylcysteine  Lower lung injury score during first week of 
treatment
Miller 2009 30 10000 I.U. heparin + 3 ml 20% N-acetylcysteine + salbuta-
mol 2,5 mg every 4 h for 7 days
Lower lung injury score, lower mortality 
Elsharnouby 
2013
29 5000 or 10000 I.U. heparin alternating with 3 ml 20% N-ace-
tylcysteine every 2 h
Lower lung injury score, no impact on 
mortality 
Kashefi 2014 40 5000 I.U. heparin + 3 ml 0.9% NaCl alternating with 3 ml 
20% N-acetylcysteine + salbutamol 2,5 mg every 4h for  
7 days 
No impact on mortality, duration of me-
chanical ventilation, higher incidence of 
pneumonia
McIntire 2016 72 10000 I.U. heparin +  salbutamol 2,5 mg + 3 ml 20% N-ace-
tylcysteine or 3 ml 4% NaHCO3 every 4 h for 7 days
Lower duration of ventilation, no impact on 
mortality or incidence of pneumonia
agulation was left to the discretion of physician 
in charge. Moreover, not all cases of inhalation 
injury were confirmed by bronchoscopy ex-
amination. The mentioned elements could have 
resulted in selection bias [33]. On the other side, 
Desai’s results were proven in small (16 patients) 
group studied by Rivero [34]. A protocol similar to 
the one employed by Holt was studied by Miller. 
Differences included an increase of heparin dose 
to 10 000 I.U. and the use of salbutamol in reg-
ular intervals. The study was designed to verify 
Desai’s results in an adult group using objective 
quantification of lung state, employing LUNG 
Injury Score originally designed to appraise 
ARDS [35]. Although the results proved a pos-
itive effect of therapy on Lung Injury Score and 
mortality, the authors remarked that they should 
be confirmed in larger, multicentre prospective 
trial [36]. The prospective HEPBURN trial was 
registered in 2013. It was planned to fill the gap 
noticed by Miller. Exclusion criteria proposed in 
the HEPBURN trial can be treated as potential 
contraindication for inhaled heparin therapy: 
history of pulmonary haemorrhage in preceding 
3 months, clinically significant coagulation dis-
order, allergy to heparin, history of thrombocy-
topenia after heparin use, pregnancy, lactation, 
aspiration, history of COPD needing chronic 
oxygen therapy or non-invasive mechanical ven-
tilation. According to ClinicalTrials.gov website, 
the HEPBURN study was terminated in 2017 
because of financial issues [37]. Elsharnouby et 
al. investigated the difference in clinical outcome 
of two different heparin doses on burn patients 
with inhalation injury. Although lower lung in-
jury scores and shorter duration of mechanical 
ventilation were achieved, it had no impact on 
mortality. It is worth noting that the both studied 
doses had no influence on coagulation test results 
[38]. The 2014 study by Kashefi et al. tried a dif-
ferent approach — study and control groups were 
matched for sex, burn severity and age. The study 
results showed statistically significant higher in-
cidence of pneumonia in the treated group (45% 
vs 11%). The study protocol assumed heparin 
administration twice less often than in previ-
ous researches, i.e. once every 8 h. The authors 
suggested that the patients could have been un-
derdosed [39]. The approach based on matching 
cohorts for burn severity and age was repeated 
in a study from centre in Indianapolis. However, 
dosing was four times higher than the one used by 
Kashefi — 10000 I.U. of heparin was administered 
every 4 hours. In contrast to the previous study, 
no impact on pneumonia was noted, yet duration 
of ventilation was significantly lowered (7 days 
vs 14.5 days) [40]. Table 1 sums up results of 
available studies. 
Side effects
The use of inhaled heparin in patients with 
burns can raise concerns about potential cli-
nically significant bleeding events. There is 
a case report about a 2-year-old male in whom 
administration of heparin according to the pro-
tocol proposed by Desai, resulted in clinically 
significant coagulopathy. Coagulation disorder 
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resolved after heparin use cessation. The authors 
concluded that in a healthy patient, clinically 
significant absorption and systemic effects after 
inhaled administration of heparin are unlikely. 
Yet, in cases of profound airway damage such 
connection can be plausible. The authors stress 
the importance of regular monitoring of coagu-
lation tests results during therapy [41]. A study 
of healthy volunteers examined potential side 
effects of inhaled heparin in doses delivered to 
the lower airways up to 32 000 I.U. (which relates 
to an administered dose of 400 000 I.U.). At that 
dosing heparin has no influence on spirometric 
values (FEV1, FVC), clinically noticeable bleeding 
or sense of dyspnoea. At the same time anti-Xa 
values and activated partial thromboplastin time 
change were statistically significant, but without 
any clinical consequences [42]. A retrospective 
study on safety of inhaled anticoagulants use in 
patients with inhalation injury was performed 
on 63 subjects. The typical time of inhalation 
therapy was 7 days, but due to a slower recovery 
in some patients, this time was elongated up to 
16 days. Anomalies in coagulation tests and bleed-
ing episode caused treatment discontinuation in 
1 patient. Nonetheless, the authors failed to prove 
connection between coagulation disorder and the 
used therapy. Obtained data confirm a lack of sig-
nificant influence of nebulised heparin on bleed-
ing risk in patients with inhalation injury [43]. 
Dixon performed a series of studies concerning 
potential therapeutic use and safety of inhaled 
heparin in various clinical situations. Clinical 
situations studied included: acute lung injury, 
invasive mechanical ventilation, state after car-
diac surgery with cardiopulmonary bypass. No 
study showed connection between heparin use 
and risk of adverse reactions, including bleed-
ing episodes. In patients with acute lung injury, 
nebulised heparin doses up to 400 000 I.U. were 
related to a rise of APPT and PT to 64 and 50 s 
respectively, without any clinical symptoms 
[44–46]. Available data confirm safety of inhaled 
heparin in various clinical settings, even in dos-
es exceeding the ones used in inhalation injury. 
Simultaneously, coagulation tests should by reg-
ularly monitored during therapy.
Conclusions
Animal models and single centre clinical 
trials proved clinical utility of inhaled heparin 
therapy in inhalation injury. This therapeutic 
approach is not connected with clinically signi-
ficant side effects or risks, including bleeding. 
There are no studies confirming heparin utility 
in multicentre, prospective trials. Basing on avail-
able evidence, we suggest that heparin is a viable 
option in inhalation injury, and its inclusion 
should be considered in all burn patients with 
confirmed airways damage.
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